UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Protecting American Bees against the Introduction of the Isle of Wight Disease

Journal of economic entomology, 1923-04, Vol.16 (2), p.133-136

1923

Volltextzugriff (PDF)

Book Shelf

Bee world, 1946-02, Vol.27 (2), p.11-12

Gooderham, C. B.

1946

Volltextzugriff (PDF)

Arena

Bee world, 1942-08, Vol.23 (8), p.61-61

Gooderham, C. B.

1942

Volltextzugriff (PDF)

The Bee World at A Glance

Bee world, 1928-07, Vol.9 (7), p.111-112

Gooderham, C. B.

1928

Volltextzugriff (PDF)

Book Shelf

Bee world, 1948-02, Vol.29 (2), p.12-13

1948

Volltextzugriff (PDF)

POPULAR AND PRACTICAL ENTOMOLOGY.: An Insect Enemy of the Parsnip

Canadian entomologist, 1916-02, Vol.48 (2), p.37-41

1916

Volltextzugriff (PDF)

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British journal of dermatology (1951), 2015-12, Vol.173 (6), p.1387-1399

2015

Volltextzugriff (PDF)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Volltextzugriff (PDF)

Our Book Shelf

Bee world, 1936-07, Vol.17 (7), p.77-78

1936

Volltextzugriff (PDF)

Impact of Structural and Metabolic Variations on the Toxicity and Carcinogenicity of Hydroxy- and Alkoxy-Substituted Allyl- and Propenylbenzenes

Chemical research in toxicology, 2014-07, Vol.27 (7), p.1092-1103

2014

Volltextzugriff (PDF)

Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study

Journal of the European Academy of Dermatology and Venereology, 2024-02, Vol.38 (2), p.340-353

2024

Volltextzugriff (PDF)

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Journal of the American Academy of Dermatology, 2023-01, Vol.88 (1), p.29-39

2023

Volltextzugriff (PDF)

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.615-622

2018

Volltextzugriff (PDF)

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody

British journal of dermatology (1951), 2019-06, Vol.180 (6), p.1352-1360

2019

Volltextzugriff (PDF)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022-06, Vol.36 (6), p.855-865

2022

Volltextzugriff (PDF)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1359-1368

2020

Volltextzugriff (PDF)

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1871-1880

2023

Volltextzugriff (PDF)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet (British edition), 2018-06, Vol.391 (10136), p.2213-2224

2018

Volltextzugriff (PDF)

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

Journal of the European Academy of Dermatology and Venereology, 2017-09, Vol.31 (9), p.1483-1490

2017

Volltextzugriff (PDF)

Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management

Journal of the European Academy of Dermatology and Venereology, 2023-04, Vol.37 (4), p.737-752

2023

Volltextzugriff (PDF)

Identification of Human Urinary Biomarkers of Cruciferous Vegetable Consumption by Metabonomic Profiling

Journal of proteome research, 2011-10, Vol.10 (10), p.4513-4521

2011

Volltextzugriff (PDF)

The sensor kinase PhoQ mediates virulence in Pseudomonas aeruginosa

Microbiology (Society for General Microbiology), 2009-03, Vol.155 (Pt 3), p.699-711

2009

Volltextzugriff (PDF)

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.797-806

2021

Volltextzugriff (PDF)

A study of the drug tildrakizumab for plaque psoriasis

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e196-e196

2020

Volltextzugriff (PDF)

药物 Tildrakizumab 治疗斑块型银屑病的研究

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e208-e208

2020

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(51)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Protecting American Bees against the Introduction of the Isle of Wight Disease

Book Shelf

Arena

The Bee World at A Glance

Book Shelf

POPULAR AND PRACTICAL ENTOMOLOGY.: An Insect Enemy of the Parsnip

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Our Book Shelf

Impact of Structural and Metabolic Variations on the Toxicity and Carcinogenicity of Hydroxy- and Alkoxy-Substituted Allyl- and Propenylbenzenes

Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management

Identification of Human Urinary Biomarkers of Cruciferous Vegetable Consumption by Metabonomic Profiling

The sensor kinase PhoQ mediates virulence in Pseudomonas aeruginosa

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

A study of the drug tildrakizumab for plaque psoriasis

药物 Tildrakizumab 治疗斑块型银屑病的研究

Suchergebnisse filtern